This is the authors' abstract. We don't add key points for this paper.
Acipimox was introduced as a nicotinic acid analogue for lipid modification, but its later use has shifted towards experimental suppression of lipolysis in human metabolic studies. We examined whether this pattern reflects loss of drug identity or mechanism-constrained reuse of an established pharmacodynamic effect. Bibliographic records from PubMed, Web of Science Core Collection and Scopus were harmonized into a frozen dataset of 863 records. A nested two-level framework defined a Broad Application Space (n = 428), within which a stricter Drug-Identity Core (n = 239) was identified. Bibliometric mapping was interpreted alongside landmark pharmacological studies to preserve a clinical pharmacology perspective. The 428-record Broad Application Space comprised 239 Drug-Identity Core records and 189 Broad-only application/probe records. The nested Core remained centred on lipid lowering, tolerability, lipolytic-enzyme regulation and suppression of free fatty acid availability, whereas the additional Broad-only literature extended into insulin sensitivity, endocrine physiology, skeletal-muscle fuel handling and nicotinamide adenine dinucleotide- and mitochondrial-linked metabolic readouts. The pivotal pharmacological signal was not a complete transformation of acipimox into a mitochondrial drug, but recurrent experimental reuse of receptor-linked antilipolysis. Acipimox illustrates how an older compound can retain value when a well-characterized pharmacodynamic action is reused as a probe of lipid substrate availability, substrate competition and selected bioenergetic readouts. Such use requires explicit attention to timing, rebound non-esterified fatty acids and tissue context.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: